Importantly, this is the first report to show that uncommon EGFR mutations without T790M mutations when initiating treatment with ICIs is a promising predictive factor to identify responders of ICIs among patients with EGFR‐mutated NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.